Virtual Library

Start Your Search

M. Cowen



Author of

  • +

    P2.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 210)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Localized Disease - NSCLC
    • Presentations: 1
    • +

      P2.02-022 - Short and Long-Term Outcomes of Pneumonectomy for Lung Cancer: 15-Years Experience (ID 201)

      09:30 - 17:00  |  Author(s): M. Cowen

      • Abstract
      • Slides

      Background:
      Surgery is the most important therapeutic modality for the treatment of lung cancer. Surgical outcomes are normally reported as 30-day or 90-day mortality or 5-year survival. However, 10-years survival is rarely mentioned in the national data or international studies.

      Methods:
      Patients included who underwent penumonectomy from January1998 to February2013, and analysed their short and long-term outcome till september2014. Thoracoscore was used to calculate the risk of hospital mortality

      Results:
      306-patients underwent pneumonectomy mainly for lung cancer. 79% were male, median age was 64-years(22-82years) and 24% were ≥ 70-years. Operative mortality was 4.5% while predicted mortality was 8%. However, operative mortality for cancer patients was 3.3% while reported national mortality for lung cancer is 6.5%. Only 2-patients died in hospital after pneumonectomy in the last 5 years. Half of the patients, who died in hospital, were ≥70-years while 29%(4-patients) died after urgent operation for non-malignant-disease. Overall 5 and 10-year survival rates were 32% and 20%. Median and mean survival was 26 and 57-months respectively. Long-term survival was better in female, patients with age <70 years, in left pneumonectomy and for squamous-cell-lung-cancer patients.

      Conclusion:
      This retrospective single institutional review have shown that our mortality for pneumonectomy is 50% less than national mortality and significantly lower than that predicted by Thoracoscore for lung cancer. This confirms that pneumonectomy is still an effective modality in the treatment of lung cancer with low operative mortality and good long-term survival especially in younger patients. It can be done safely with good short and long-term outcome by trained experienced surgeons.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.